Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 4;22(1):404–428. doi: 10.1080/14686996.2021.1924044

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published by National Institute for Materials Science in partnership with Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 9. — (a) Preparation scheme of BP-BG composite scaffolds. (b) Infrared thermographic photographs of osteosarcoma-bearing nude mice implanted with BG and BP-BG scaffolds. (c) Tumor growth curves of mice after different treatments. (d) Photographs of osteosarcoma-bearing mice after different treatments on day 14. (e) Micro-CT imaging after treatment for 8 weeks. The defect areas were implanted with BP-BG and BG scaffold, respectively. (f) Stepwise therapeutic strategy for the elimination of osteosarcoma followed by osteogenesis in BP-BG composite scaffolds. Reproduced with permission [162]. (g) Preparation scheme of nanofibrous scaffolds and the underlying mechanisms of PTT/chemotherapy and tissue regeneration. (h) Representative images of the tumors on days 0, 4, 8, 12 and 15 after treatment with control (I), GP (II), GP+laser (III), 5BP-PEG-FA-GP (IV), 5BP-PEG-FA-GP+laser (V), 5BP@DOX-PEG-FA-GP (VI) and 5BP@DOX-PEG-FA-GP+laser (VII). (i) Representative images of dermal wounds in different treatment groups on days 0, 4, 8, 12 and 15. The treatments include control (I), GP(II), 5BP-PEG-FA-GP (III) and 5BP@DOX-PEG-FA-GP (IV). Reproduced with permission [163]